Bleomycin-induced lung injury: Revisiting an old tool to model group III PH associated with pulmonary fibrosis.

Santos-Ribeiro, Diana [UCL] Lecocq, Marylène [UCL] De Beukelaer, Michèle [UCL] Bouzin, Caroline [UCL] Palmai-Pallag, Mihaly [UCL] Yakoub, Yousef [UCL] Huaux, François [UCL] Horman, Sandrine [UCL] Perros, Frederic Pilette, Charles [UCL] Godinas, Laurent [UCL] et al.[show all]

Pulmonary hypertension (PH) is a chronic disorder of the pulmonary circulation that often associates with other respiratory diseases (i.e., group III PH), leading to worsened symptoms and prognosis, notably when combined with interstitial lung diseases such as pulmonary fibrosis (PF). PH may lead to right ventricular (RV) failure, which accounts for a substantial part of the mortality in chronic lung disease patients. The disappointing results of pulmonary arterial hypertension (PAH)-related therapies in patients with PF emphasize the need to better understand the pathophysiologic mechanisms that drive PH development and progression in this specific setting. In this work, we validated an animal model of group III PH associated with PF (PH-PF), by using bleomycin (BM) intratracheal instillation and characterizing the nature of induced lung and vascular remodeling, including the influence on RV structure and function. To our knowledge, this is the first work describing this dose of BM in Sprague Dawley rats and the effects upon the heart and lungs, using different techniques such as echocardiography, heart catheterization, and histology. Our data shows the successful implementation of a rat model that mimics combined PF-PH, with most features seen in the equivalent human disease, such as lung and arterial remodeling, increased mPAP and RV dysfunction.